Tenax Therapeutics To Participate In The Guggenheim Emerging Outlook Biotech Summit 2026

2026-02-04 07:01:50

(MENAFN- GlobeNewsWire - Nasdaq) CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or“Tenax Therapeutics” or the“Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.

Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business Officer
Date and Time: February 11, 2026, at 12:30 p.m. ET

The live and archived webcast of the presentation will be accessible from the Company's investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit . Tenax Therapeutics' common stock is listed on The Nasdaq Stock Market LLC under the symbol“TENX”.

Contact:

Investor and Media:

Argot Partners

...

MENAFN04022026004107003653ID1110694157

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.